Depomed, Inc. (NASDAQ:DEPO) and Rottapharm/Madaus announced today that the Marketing Authorization (MA) for ProQuin XR has been received from the Medical Products Agency in Sweden. Depomed's ProQuin XR is exclusively licensed to Rottapharm/Madaus for Europe and is a once-daily extended-release formulation of ciprofloxacin hydrochloride for the treatment of uncomplicated urinary tract infections.
"We are glad to see ProQuin XR be approved in Sweden as reference member state which is a first step to make it commercially available in Europe. We feel confident that our partner Rottapharm/Madaus with their strong market presence and local expertise in individual European countries will realize ProQuin XR's commercial potential in Europe. We anticipate the commercial rollout and pricing in other European countries will progress through next year," noted Carl A. Pelzel, president and chief executive officer of Depomed.
The details can be read here.
No comments:
Post a Comment